A patient with one of the most aggressive forms of acute myeloid leukemia relapsed after a stem cell transplant, the last line of defense doctors typically have left. Instead of running out of options, his medical team tried something that hadn't been possible before: a targeted CAR-T therapy that could attack his cancer cells while leaving his newly rebuilt healthy blood system completely untouched. More than a year later, he remains in complete remission.

That case sits at the center of a clinical trial led by researchers at Washington University School of Medicine in St. Louis, published this week in Nature Medicine, testing a CRISPR gene-editing strategy designed to solve one of the most stubborn problems in blood cancer treatment: how to attack cancer cells aggressively without also destroying the healthy donor cells a transplant patient depends on to survive.

The problem this trial was built to solve

For patients with high-risk acute myeloid leukemia, or AML, and myelodysplastic syndrome, or MDS, a stem cell transplant remains one of the only treatments with real curative potential. Even so, relapse remains a persistent threat, and doctors' options narrow considerably once cancer returns after transplantation. Targeted immunotherapies aimed at a protein called CD33, commonly found on both leukemia cells and healthy blood-forming cells, have shown promise against relapsed disease. The catch is right there in that shared protein: a CD33-targeted therapy can't distinguish between the cancer cells doctors want to kill and the healthy donor cells the patient needs to survive.

"As such, the anti-cancer therapy carries a high risk of toxicity because it also destroys healthy blood stem cells," explained John F. DiPersio, the trial's senior author and director of WashU Medicine's Center for Gene and Cellular Immunotherapy, according to reporting from AOL that summarized the study's findings.

How CRISPR solves a targeting problem, not a cancer problem

The team's approach doesn't attack the cancer directly at all. Instead, before transplantation, researchers used CRISPR gene editing to remove the CD33 protein entirely from donor stem cells, creating what's known as CD33-deleted stem cells. Once those edited cells engraft and rebuild a patient's blood system, any cells still carrying CD33 in that patient's body should, in theory, be almost exclusively cancer cells, since the healthy donor-derived population no longer expresses the marker at all.

That distinction matters enormously for treatment strategy. A CD33-targeted immunotherapy, whether a straightforward drug or a more sophisticated CAR-T cell therapy, could then be deployed far more aggressively against relapsed disease, since it would no longer be simultaneously wiping out the newly rebuilt healthy blood supply alongside the cancer. CD33 was chosen specifically because the protein is found only on blood-forming cells and nowhere else in the body, and because people born without functional CD33 don't appear to experience related health problems, according to Mirage News's coverage of the trial's rationale.

What actually happened in the 30-patient trial

The phase 1/2 multicenter trial enrolled 30 adults with high-risk AML or MDS, 29 with AML and one with MDS, all considered at elevated risk of relapse, according to AOL's reporting on the study. Each patient received donor stem cells modified with CRISPR to delete CD33 before transplantation. The resulting engineered cell product, developed and funded by Vor Biopharma, carries the name tremtelectogene empogeditemcel, or trem-cel for short.

The core safety finding was reassuring on its own terms: the CD33-deleted transplants engrafted successfully and produced outcomes closely resembling standard stem cell transplantation. "We are encouraged by the results of this study showing that a CD33-deleted stem cell transplant looks very similar to the outcomes of standard stem cell transplantation," DiPersio said, according to ScienceDaily's coverage of the findings. That similarity matters because it means the genetic modification itself doesn't appear to introduce new risks or complications beyond what patients already face with a conventional transplant.

The follow-up treatment that proved the concept

Beyond the engraftment data, researchers reported a specific case that demonstrated the strategy's real-world potential. A patient with high-risk AML who had received a CD33-deleted stem cell transplant later relapsed. Rather than facing the usual trade-off between attacking the cancer and preserving the rebuilt blood system, doctors treated the patient with CD33-targeted CAR-T cells manufactured from T cells provided by the same donor who had supplied the original stem cells.

According to Mirage News's reporting on the case, the patient entered complete remission and remained cancer-free more than a year after CAR-T treatment. Normal blood cell production returned as well, and critically, all of the patient's blood cells lacked CD33, direct evidence that the genetically engineered donor cells had successfully and durably established themselves in the bone marrow long after the initial transplant.

Why this matters beyond the specific patients treated

DiPersio framed the trial's broader significance around what it enables next, rather than treating it as a finished therapy on its own. "In the future, we are hopeful we will be able to combine this with CD33-targeted immunotherapies, such as CAR-T cells, and improve treatment options for patients with these very aggressive blood cancers," he said, according to ScienceDaily.

That framing matters because the trial itself primarily demonstrates safety and feasibility, that CD33-deleted stem cells can engraft normally and behave like standard donor cells, rather than proving the full combination therapy's effectiveness against relapsed disease at scale. The single documented CAR-T follow-up case offers a genuinely encouraging proof of concept, but it's one patient's outcome, not yet a validated treatment pathway backed by controlled trial data across a larger population.

What still needs to happen before this reaches routine care

This is explicitly early-phase research, and the study's authors have been clear that larger trials with longer follow-up periods remain necessary before CD33-deleted transplants paired with CD33-targeted immunotherapy could become a standard treatment option, according to reporting from AOL. Questions that remain open include how consistently the pairing produces durable remissions across a broader patient population, how it performs against different genetic subtypes of AML and MDS, and whether the strategy's benefits hold up as follow-up data extends well beyond the roughly one-year mark documented in this initial case.

Vor Biopharma's continued development of trem-cel will likely determine how quickly this specific approach moves toward larger confirmatory trials. In the meantime, the underlying strategy, engineering donor cells to be genetically invisible to a specific cancer treatment before that treatment is ever administered, offers a template that researchers working on other blood cancers, and potentially other cancer types entirely, may look to adapt using different target proteins matched to their own disease's biology.